Intensive Care Medicine

, Volume 31, Issue 5, pp 649–655 | Cite as

Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings

  • José Garnacho-Montero
  • C. Ortiz-Leyba
  • Esteban Fernández-Hinojosa
  • Teresa Aldabó-Pallás
  • Aurelio Cayuela
  • Juan A. Marquez-Vácaro
  • Andrés Garcia-Curiel
  • F. J. Jiménez-Jiménez



To investigate prognostic factors and predictors of Acinetobacter baumannii isolation in ventilator-associated pneumonia (VAP). We specifically analyzed these issues for imipenem-resistant episodes.

Design and setting

All episodes of VAP are prospectively included in a database. Information about risk factors was retrieved retrospectively.


Eighty-one patients exhibiting microbiologically documented VAP: 41 by A. baumannii (26 by imipenem-resistant) and 40 by other pathogens.

Measurements and results

The following variables were noted: underlying diseases, severity of illness, duration of mechanical ventilation and of hospitalization before VAP, prior episode of sepsis, previous antibiotic, corticosteroid use, type of nutrition, renal replacement therapy, reintubation, transportation out of the ICU, micro-organisms involved in VAP, concomitant bacteremia, clinical presentation, Sequential Organ Failure Assessment (SOFA) scale on the day of diagnosis, and adequacy of empirical antibiotic therapy. Prior antibiotic use was found to be associated with development of VAP by A. baumannii (OR 14). Prior imipenem exposure was associated with the isolation of imipenem-resistant strains (OR 4). SOFA score on the day of diagnosis was the only predictor of in-hospital mortality (OR 1.22); adequacy of empirical antibiotic therapy was a protective factor (OR 0.067).


Our results confirm that prior exposure to antimicrobials is an independent predictor for the development of A. baumannii VAP, the prognosis of which is similar to that of infections caused by other pathogens. This study highlights the importance of initial antibiotic choice in VAP or whatever cause.


Acinetobacter baumannii Ventilator-associated pneumonia Severity of illness Prognosis Bacteremia Initial antibiotic therapy 


  1. 1.
    Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J (1999) Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 160:608–613Google Scholar
  2. 2.
    Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA (2002) Comparison of ampicillin-sulbactam and imipenem-cilastatin for treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 34:1425–1430Google Scholar
  3. 3.
    Erbay H, Yalcin AN, Serin S, Turgut H, Tomatir E, Cetin B, Zencir M (2003) Nosocomial infections in intensive care unit in a Turkish university hospital: a 2-year survey. Intensive Care Med 29:1482–1488Google Scholar
  4. 4.
    Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, Flores C, Brooks S (2002) Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY. Arch Intern Med 162:1515–1520Google Scholar
  5. 5.
    Baraibar J, Correa H, Mariscal D, Gallego M, Valles J, Rello J (1997) Risk factors for infection by Acinetobacter baumannii in intubated patients with pneumonia. Chest 112 1050–1054Google Scholar
  6. 6.
    Husni RN, Goldstein LS, Arroliga AC et al (1999) Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 115:1378–1382Google Scholar
  7. 7.
    Richet HM, Mohammed J, McDonald LC, Jarvis WR (2001) Building communication networks: International Network for the Study of Emerging Antimicrobial Resistance. Emerg Infect Dis 7:319–322Google Scholar
  8. 8.
    Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, Mosinka-Snipas K, Rahal JJ (1994) Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polimixin B and sulbactam. Lancet 344:1329–1332Google Scholar
  9. 9.
    Corbella X, Montero A, Pujol M, Dominguez MA, Ayats J, Argerich MJ, Garrigosa F, Ariza J, Gudiol F (2000) Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 38:4086–4095Google Scholar
  10. 10.
    Lee SO, Kim NJ, Choi SH, Hyong Kim T, Chung JW, Woo JH, Ryu J, Kim YS (2004) Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 48:224–228Google Scholar
  11. 11.
    Garnacho Montero J, Ortiz Leyba C, Fernández Hinojosa E, Cayuela A, Aldabó Payas T, Jiménez FJ (2004) Risk factor for infection by Acinetobacter baumannii in patients with ventilator associated pneumonia: analysis of imipenem resistant episodes. Abstracts, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington pp 351–352Google Scholar
  12. 12.
    Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittel M, Gallego-Lara SL, Madrazo-Osuna J (2003) Treatment of multiresistant Acinetobacter baumannii ventilator-associated pneumonia with intravenous colistin: a comparison with imipenem susceptible espisodes. Clin Infect Dis 36:1111–1118Google Scholar
  13. 13.
    Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J (2003) Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: A matched cohort study. Crit Care Med 31:2478–2482Google Scholar
  14. 14.
    National Committee for Clinical Laboratory Standards (NCCLS) (2000) Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 5th edn. Approved Standards Document M7-A5. NCCLS, Wayne, PennsylvaniaGoogle Scholar
  15. 15.
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II, a severity of disease classification system. Crit Care Med 13:818–829PubMedGoogle Scholar
  16. 16.
    Pittet D, Thiévent B, Wenzel RP, Li N, Gurman G, Suter PM (1993) Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Med 19:265–272Google Scholar
  17. 17.
    Rello J, Torres A, Ricart M (1994) Ventilator-associated pneumonia by Staphylococcus aureus. Am J Respir Crit Care Med 150:1545–1549Google Scholar
  18. 18.
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee (1992) Definition for sepsis and organ failures and guidelines for the use of innovative therapies in sepsis. Chest 101:1658–1662Google Scholar
  19. 19.
    Hosmer DW, Lemeshow SA (1989) Applied logistic regression. Wiley, New YorkGoogle Scholar
  20. 20.
    Gómez J, Simarro E, Baños V, Requena L, Ruiz J, García F, Canteras M, Valdés M (1999) Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 18:358–361Google Scholar
  21. 21.
    Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Perez-Paredes C, Barrero-Almodovar AE, Gili-Miner M (2001) Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: A cohort study. Clin Infect Dis 33:939–946Google Scholar
  22. 22.
    Mulin B, Talon D, Viel JF (1995) Risk factors for nosocomial colonization with multiresistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 14:569–576Google Scholar
  23. 23.
    Villers D, Espaze E, Coste-Burel M, Giauffret F, Ninin E, Nicolas F, Richet H (1998) Nosocomial Acinetobacter baumannii infections microbiological and clinical epidemiology. Ann Intern Med 129:182–189Google Scholar
  24. 24.
    Torres A, Gatell JM, Aznar E, el-Ebiary M, Puig de la Bellacasa J, Gonzalez J, Ferrer M, Rodriguez-Roisin R (1995) Re-intubation increases the risk of nosocomial pneumonia in patient needing mechanical ventilation. Am J Respir Crit Care Med 152:137–141Google Scholar
  25. 25.
    Aarst MA, Marshall JC (2003) Empiric antibiotics in critical illness: do they help or harm? In: Vincent JL (ed) Yearbook of intensive care and emergency medicine. Springer, Berlin Heidelberg New York, pp 219–228Google Scholar
  26. 26.
    Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C (1993) Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay. Am J Med 94:281–288CrossRefPubMedGoogle Scholar
  27. 27.
    Kollef MH, Sharpless L, Vlasnik J, Pasque C, Murphy D, Fraser VJ (1997) The impact of nosocomial infections on patient outcomes following cardiac surgery. Chest 112:666–675Google Scholar
  28. 28.
    Alvarez-Lerma and the ICU-Acquired Pneumonia Study Group (1996) Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 22:387–394Google Scholar
  29. 29.
    Rello J, Gallego M, Mariscal D, Soñora R, Vallés J (1997) The value of routine microbiological investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 156:196–200PubMedGoogle Scholar
  30. 30.
    Kollef MH, Ward S (1998) The influence of mini-BAL cultures on patient outcome: Implications for the antibiotic management of ventilator-associated pneumonia. Chest 113:412–420PubMedGoogle Scholar
  31. 31.
    Duppont H, Mentec H, Sollet JP, Bleichner G (2001) Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 27:355–362Google Scholar
  32. 32.
    Leroy O, Meybeck A, d’Escrivan T, Devos P, Kipnis E, Georges H (2003) Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med 29:2170–2173Google Scholar
  33. 33.
    Dupont H, Montravers P, Gauzit R et al (2003). Outcome of postoperative pneumonia in the Eole study. Intensive Care Med 2003 29:179–188Google Scholar
  34. 34.
    Luna CM, Videla A, Mattera J, Vay C, Famiglietti A, Vujacich P, Niederman MS (1999) Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. Chest 116:1075–1084CrossRefPubMedGoogle Scholar
  35. 35.
    Kollef MH (1993) Ventilator-associated pneumonia. A multivariate analysis. JAMA 270:1965–1970CrossRefPubMedGoogle Scholar
  36. 36.
    Rello J, Rue M, Jubert P, Muses G, Sonora R, Valles J, Niederman MS (1997) Survival in patients with nosocomial pneumonia: Impact of the severity of illness and etiologic agents. Crit Care Med 25:1862–1867CrossRefPubMedGoogle Scholar
  37. 37.
    Mulin B, Rouget C, Clement C, Bailly P, Julliot MC, Viel JF, Thouverez M, Vieille I, Barale F, Talon D (1997) Association of private isolation rooms with ventilator-associated Acinetobacter baumannii pneumonia in a surgical intensive care unit. Infect Control Hosp Epidemiol 18:499–503Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • José Garnacho-Montero
    • 1
  • C. Ortiz-Leyba
    • 1
  • Esteban Fernández-Hinojosa
    • 1
  • Teresa Aldabó-Pallás
    • 1
  • Aurelio Cayuela
    • 2
  • Juan A. Marquez-Vácaro
    • 1
  • Andrés Garcia-Curiel
    • 3
  • F. J. Jiménez-Jiménez
    • 1
  1. 1.Intensive Care UnitHospital Universitario Virgen del RocíoSevilleSpain
  2. 2.Supportive Research UnitHospital Universitario Virgen del RocíoSevilleSpain
  3. 3.Microbiology ServiceHospital Universitario Virgen del RocíoSevilleSpain

Personalised recommendations